Spatz Quoted in WSJ Pro Venture Capital on Potential Impact of Recent Drug Pricing Executive Orders

Venture Capitalists Push Back on Trump Drug-Pricing Measure
– WSJ Pro Venture Capital

Manatt Health senior advisor Ian Spatz spoke with WSJ Pro Venture Capital on President Trump’s recent decision to issue a series of executive orders aimed at lowering prescription drug costs, and the impact they might on investment in biotechnology. In particular, Spatz discussed one of the executive order’s impact on Medicare prices for medications under Part B, saying, “pegging Medicare Part B prices to international prices could have a significant impact on the profitability of current drugs and the development of new medicines that would be covered under this program.”



pursuant to New York DR 2-101(f)

© 2023 Manatt, Phelps & Phillips, LLP.

All rights reserved